|
| |
| | | | 1 | | | DO1.PCCNTR.1254866 ContractData Container |
| | | 1.1 | | | | | | | | | | 129,915,000.00 | 0.00 | 0.00 | 0.00 | 133,714,200.00 | 129,915,000.00 |
|
| | | | | | | 1 | | 2.3.4.1.01 | Atezolizumab 1200 mg/20 ml vial | 63 | UD | 390,000 | 384,000 | 24,192,000.00 | | 0.00 | | 0 | 0.00 | | 0.00 | 24,570,000.00 | 24,192,000.00 | |
|
| | | | | | | 4 | | 2.3.4.1.01 | Dornasa Alfa 2.5 mg/2.5 ml amp. | 500 | UD | 2,350 | 2,350 | 1,175,000.00 | | 0.00 | | 0 | 0.00 | | 0.00 | 1,175,000.00 | 1,175,000.00 | |
|
| | | | | | | 5 | | 2.3.4.1.01 | Emicizumab 30 mg/ 1ml vial | 250 | UD | 110,000 | 110,000 | 27,500,000.00 | | 0.00 | | 0 | 0.00 | | 0.00 | 27,500,000.00 | 27,500,000.00 | |
|
| | | | | | | 6 | | 2.3.4.1.01 | Emicizumab 105 mg /0.7 ml vial | 41 | UD | 385,000 | 382,000 | 15,662,000.00 | | 0.00 | | 0 | 0.00 | | 0.00 | 15,785,000.00 | 15,662,000.00 | |
|
| | | | | | | 7 | | 2.3.4.1.01 | Obinutuzumab 1000mg/40 ml vial | 10 | UD | 97,500 | 99,800 | 998,000.00 | | 0.00 | | 0 | 0.00 | | 0.00 | 975,000.00 | 998,000.00 | |
|
| | | | | | | 8 | | 2.3.4.1.01 | Pertuzumab 420 mg/ 14 ml vial | 191 | UD | 197,000 | 197,000 | 37,627,000.00 | | 0.00 | | 0 | 0.00 | | 0.00 | 37,627,000.00 | 37,627,000.00 | |
|
| | | | | | | 12 | | 2.3.4.1.01 | Trastuzumab 600 mg/ 5 ml vial | 266 | UD | 73,000 | 63,000 | 16,758,000.00 | | 0.00 | | 0 | 0.00 | | 0.00 | 19,418,000.00 | 16,758,000.00 | |
|
| | | | | | | 14 | | 2.3.4.1.01 | Tocilizumab 80 mg/ 4 ml vial | 870 | UD | 7,660 | 6,900 | 6,003,000.00 | | 0.00 | | 0 | 0.00 | | 0.00 | 6,664,200.00 | 6,003,000.00 | |
|
|
| | | |
| | | |
|